The genetic tests clinicians use to diagnose and stratify breast cancer are getting increasingly complex and studies show that there may be some discordance between generations when assessing a woman’s risk of cancer recurrence. Molecular subtyping may be the only way to gain clarity. 

Typical Alzheimer’s neuroimaging looks at amyloid deposition and neurofibrillary tangles, but a new quantitative method uses arterial input to bring signs of functional disease into sharper relief, according to a study published April 16 in the Journal of Nuclear Medicine.

The FDA is collaborating with a number of Alzheimer’s groups including the Alzheimer’s Association within the community to support the development of new biomarkers and improved diagnosis.

If an ovarian cell carries a certain genetic variant it could spell an excess of androgens much like testosterone in women with polycystic ovary syndrome, making it more difficult for them to conceive. This revelation could eventually lead to a diagnostic test and treatment, according to an announcement yesterday from the National Institutes of Health.

Among the many requirements a hospital must meet to achieve and maintain the designation of Critical Access Hospital (CAH), the hospital must be fairly remote and furnish 24-hour emergency care services seven days a week, using either on-site or on-call staff.

This issue isn't about false positives, it is about subjecting patients to treatment after mammography finds a small lesion, but when in all actuality that spot on the scan poses no real threat to the patient. Some cancers are never progressive and do not require serious treatment when to do so would come with its own risks and potential complications.

ABT Molecular Imaging has successfully implemented the first BG-75 Biomarker Generator in Russia. The project was completed in cooperation with the Diagnostic and Treatment Center of the International Institute of Biological Systems (DTC IIBS), St. Petersburg, Russia, and its U.S. representative, Owen Kane Molecular Imaging, Inc. (Owen Kane). 

The global market for diagnostic biomarkers detecting cardiovascular disease is expected to soar steadily at a compound annual growth rate of 12.8 percent between 2013 and 2018.